Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The Phase 1 trial of DA-1726 is progressing well, and we expect to both dose the first patient in the multiple ascending dose (MAD) Part 2 and read-out top-line data from the single ascending dose (SAD) Part 1 in the third quarter of this year, with top-line data from the MAD Part 2 expected in the first quarter of 2025." Abstract Title: DA-1726, a GLP1R/GCGR Dual Agonist, A Promising Approach in Obesity Treatment and Lipid Management Presenter Name: Tae-Hyoung Kim, Lead research scientist, Dong-A ST Research Center Authors: Tae-Hyoung Kim, Il-Hun Jung, Su Jin Lee, Hyung Heon Kim, Mi-Kyung Kim, Yuna Chae Abstract Number: 2024-LB-5728 Poster Presentation Number: 2058-LB Session: 23-A Obesity-Animal Session Date: Saturday, June 22, 2024 Session Time: 12:30 pm 1:30 pm ET DA-1726 is currently in a Phase 1 clinical trial
It appears in plasma, saliva, and urine
AOD-9604 targets fat cells through selective activation of beta-3 adrenergic receptors on adipocytes, triggering lipolysis (fat breakdown) while simultaneously inhibiting lipogenesis (new fat formation)
P.ReddyV
GHK-Cus mechanism depends on gradual tissue accumulation over the cycle, not on high single-day concentrations
A randomized controlled trial published in the European Journal of Nutrition found that daily consumption of 500-1,000mg of glutathione supplements can be effective at increasing the storage of GSH
US$ 24.33
US$ 26.33
US$ 27.94
US$ 20.78
